Abstract: A method of monitoring execution in an execution environment of an operation, for example a cryptographic operation, comprising a sequence of instructions, is disclosed. Instructions sent in the sequence from a main processor to one or more auxiliary processors, for example cryptographic processors, to execute the operation are monitored and the sequence of instructions is verified using verification information. The method comprises enabling output from the execution environment of a result of the operation in response to a successful verification of the sequence, or generating a verification failure signal in response to a failed verification of the sequence.

Abstract: The invention provides heterodimer bispecific antigen-binding molecules that include a first polypeptide that does not include an IgG CH1 domain and a second polypeptide where there is at least one mutation in the IgG CH3 domain that abolishes the ability of the second polypeptide to bind CH3-specific affinity media such that the first and second polypeptides have different affinities with respect to CH1 and CH3 specific affinity reagents that allows rapid isolation by differential binding. The invention also provides bispecific antibodies that have CH1 and CH3 regions with different affinities with respect to affinity reagents that allows rapid isolation by differential binding. The invention also concerns bispecific antibodies which are heterodimers of two IgG heavy chains that differ by at least two amino acids that allow for rapid isolation based on a differential affinity of one mutated heavy chain and a second mutated heavy chain toward two different affinity reagents.

Abstract: The invention also relates to novel bispecific antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD47 and the second is specific for mesothelin (MSLN).

Abstract: The disclosure relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind CD3 epsilon (CD3?), as well as methods of making and using these anti-CD3? antibodies and antigen binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.

Abstract: The invention relates to monoclonal and/or monovalent antibodies that bind CD47. The invention relates to monoclonal and/or monovalent antibodies that bind CD19. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD47. The invention also relates to novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, where one of the binding sites is specific for CD19.

Abstract: A method to protect a device key in a device comprising at least one secure element locally connected to at least one time programmable memory storing a global value in form of a bit string comprising locked bits and unlocked bits. The locked bits are irreversibly pre-programmed in the one-time-programmable memory during an initialization phase of the device while the un-locked bits remaining in an initial state may be programmable by the secure element. The secure element is configured to generate, at initialization of the device, a device specific value by using the global value, program the device specific value previously obtained in the one time programmable memory, and erase the global value by programming the unlocked bits of the corresponding bit string. A further object of the disclosure includes a device configured to carry out the method.

Abstract: Disclosed are antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and diagnostic agents.

Abstract: The present invention is related to antibodies directed to the antigen CD3 and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies directed to CD3. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FRI through FR4 or CDRI through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

Abstract: Methods and devices in accordance with the disclosure relate to the secure provision of one or more keys or key pairs to protect secret data for, or associated, with a computing device. The device is typically a computing device with at least one processor or processing module configured for executing one or more applications using the secret data. The present disclosure ensures secure key provisioning by ensuring that each key in a key pair, or at least one key among a plurality of keys is associated with a device or hardware module that is distinct to the device(s) or hardware module associated with the other or remaining keys. For asymmetric key provisioning, this relates to utilizing digital signatures verified by separate devices. For symmetric key provisioning, this relates to utilizing a secret key derivation function that will operates with secret seeds that are input from two separate sources.

Abstract: The present disclosure includes methods, devises and systems for preparing and installing one or more application keys owned by application owners in a remote device. The present disclosure further proposes methods, devices and systems for secure installation of subsequent application keys on a device utilising corresponding key derivation functions to associate an application with a respective policy and identifier using significantly low bandwidth for transfer of keys for execution of the respective application on the device.

Abstract: The present invention is related to antibodies directed to the antigen CD3 and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies directed to CD3. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

Abstract: The invention relates to antigen-binding proteins or antibodies having heterodimers of heavy chains, i.e., two immunoglobulin heavy chains that differ by at least one or two amino acid(s) that allows for isolation of the antigen-binding protein based on a differential affinity of an immunoglobulin heavy chain and a modified/mutated immunoglobulin heavy chain toward an affinity reagent. The invention also relates antigen-binding proteins, including bispecific antibodies, having IgG CH1 regions with different affinities with respect to affinity reagent(s) that allows rapid isolation by differential binding of the IgG regions to the affinity reagent(s).

Abstract: Disclosed are antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and diagnostic agents.

Abstract: Provided herein are display systems for simultaneously displaying two different ligand binding polypeptides at the surface of a phage. Also provided are kits, methods of using such display systems and methods of discovering novel bispecific antibodies.

Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-CD19 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind CD19, as well as methods of making and using these anti-CD19 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.

Abstract: The invention provides novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule and methods for producing novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule. The antibodies are composed of a single heavy chain and two different light chains, one containing a Kappa constant domain and the other of a Lambda constant domain. The invention provides methods for the isolation of antibodies of different specificities but sharing a common heavy chain. The invention also provides methods for the controlled co-expression of two light chains and a single heavy chain leading to the assembly of monospecific and bispecific antibodies.

Abstract: The present invention relates in particular to a pairing method between a multimedia unit and one operator having an operator identifier, the multimedia unit having a multimedia unit identifier and receiving conditional access data from said operator, the method being characterized in that: receiving by the multimedia unit a multimedia unit key formed by applying a first cryptographically function to a personalization key and to the multimedia unit identifier; receiving by the operator an operator key formed by applying a second cryptographically function to said personalization key and to the operator identifier; said multimedia unit further having a function of the multimedia unit and said operator further having a function of the operator, these functions being such that the result of the application of the function of the operator to said operator key and to said multimedia unit identifier is equal to the result of the application of the function of the multimedia unit to said multimedia unit key a

Abstract: The invention relates to antigen-binding proteins or antibodies having heterodimers of heavy chains, i.e., two immunoglobulin heavy chains that differ by at least one or two amino acid(s) that allows for isolation of the antigen-binding protein based on a differential affinity of an immunoglobulin heavy chain and a modified/mutated immunoglobulin heavy chain toward an affinity reagent. The invention also relates antigen-binding proteins, including bispecific antibodies, having IgG CH1 regions with different affinities with respect to affinity reagent(s) that allows rapid isolation by differential binding of the IgG regions to the affinity reagent(s).

Abstract: The disclosure relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind CD3 epsilon (CD3?), as well as methods of making and using these anti-CD3? antibodies and antigen binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.

Abstract: A method to protect a device key in a device comprising at least one secure element locally connected to at least one time programmable memory storing a global value in form of a bit string comprising locked bits and unlocked bits. The locked bits are irreversibly pre-programmed in the one-time-programmable memory during an initialization phase of the device while the un-locked bits remaining in an initial state may be programmable by the secure element. The secure element is configured to generate, at initialization of the device, a device specific value by using the global value, program the device specific value previously obtained in the one time programmable memory, and erase the global value by programming the unlocked bits of the corresponding bit string. A further object of the disclosure includes a device configured to carry out the method.